Advancing Personalized Cancer Vaccines: IMMUNEO’s BITAP Project Receives Support from Brandenburg’s ProFIT Innovation Program
IMMUNEO Therapeutics GmbH is pleased to announce the successful approval of its ProFIT Brandenburg innovation grant. The funded research project, “BITAP – BioInformatic Therapy Address Peptides,” focuses on developing next-generation, AI-powered peptide immunotherapies designed for highly personalized and group-specific cancer treatment strategies.
Over the next 29 months, IMMUNEO will expand its research and development activities at the University Hospital Brandenburg an der Havel and the Medical School Brandenburg (MHB). Supported by the ProFIT program administered by Investitionsbank des Landes Brandenburg (ILB) and coordinated with WFBB (Brandenburg Economic Development Corporation), the project aims to establish a cutting-edge bioinformatics and immunology platform that combines machine learning, peptide design, and tumor genomics. The technology will enable precise identification of tumor-specific neoantigens and their translation into patient-tailored BITAP immunizations and standardized Pan-BITAP vaccines for cancer patients with shared molecular signatures, for example, those suffering from pancreatic cancer (PDAC).
The ProFIT funding will enable IMMUNEO to strengthen its R&D presence in Brandenburg, create several new scientific positions, and establish on-site laboratory infrastructures for bioinformatics and immunological platform development. By integrating artificial intelligence with state-of-the-art peptide technology, IMMUNEO sets out to improve treatment precision, reduce manufacturing complexity, and bring effective immunotherapies one step closer to real-world cancer care.
This milestone underscores IMMUNEO’s mission to pioneer innovative, safe, and affordable immunotherapies, positioning the company as one of the emerging biotech innovators bridging AI-driven peptide discovery and clinical translation in Europe.
Back to all updates